A number of other research analysts also recently issued reports on CERS. Cantor Fitzgerald reiterated an overweight rating and issued a $5.00 price target on shares of Cerus in a report on Friday, January 5th. Zacks Investment Research downgraded Cerus from a hold rating to a sell rating in a report on Tuesday, January 30th. BidaskClub upgraded Cerus from a strong sell rating to a sell rating in a report on Friday, January 5th. ValuEngine upgraded Cerus from a strong sell rating to a sell rating in a report on Thursday, January 4th. Finally, Robert W. Baird reiterated a buy rating and issued a $5.00 price target on shares of Cerus in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $5.00.
Shares of Cerus (NASDAQ CERS) opened at $5.05 on Friday. The company has a current ratio of 3.89, a quick ratio of 3.26 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $628.29, a price-to-earnings ratio of -9.02 and a beta of 2.16. Cerus has a 1 year low of $1.93 and a 1 year high of $5.43.
Large investors have recently made changes to their positions in the company. BB&T Securities LLC purchased a new position in shares of Cerus in the 3rd quarter valued at $100,000. Teacher Retirement System of Texas purchased a new position in shares of Cerus in the 4th quarter valued at $126,000. MetLife Investment Advisors LLC purchased a new position in shares of Cerus in the 4th quarter valued at $197,000. Voya Investment Management LLC increased its holdings in shares of Cerus by 22.0% in the 2nd quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock valued at $147,000 after acquiring an additional 10,570 shares during the period. Finally, Turner Investments LLC purchased a new position in shares of Cerus in the 3rd quarter valued at $177,000. Institutional investors and hedge funds own 56.27% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3258401/cerus-cers-hold-rating-reaffirmed-at-btig-research.html.
Cerus Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.